07:33 EDT Soleno jumps 11% to $63.37 after Acadia trial miss
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Positive Market Outlook for Soleno Therapeutics’ Vykat XR in Prader-Willi Syndrome Treatment
- Wells Fargo would be buyers of Soleno amid FAERS update weakness
- Soleno Therapeutics Addresses FDA Adverse Event Report
- Soleno concludes serious adverse reported in FAERS not related to VYKAT XR
- LifeScience Cap’s Optimistic Outlook on Soleno Therapeutics: Vykat XR’s Promising Market Potential and Expansion Plans